Drugmakers faced scrutiny over price increases, while banks fell as investors worried about the stability of Deutsche Bank and other financial institutions. Quincy Krosby, market strategist for Prudential Financial, said investors don't trust Deutsche Bank's statements about its financial health and they are worried what will happen to the bank and to...
TRENTON, N.J.— Drug giant Pfizer says it won't split into two publicly traded companies, despite pressure from investors frustrated by its lagging stock price, ending years of Wall Street speculation over its strategy and future. Pfizer has said it spent $600 million on preparations for such a split. As a result, Pfizer has been reporting detailed financial...
Ascena Retail Group Inc., down $2.43 to $5.69. Lennar Corp., down $1.59 to $43.50. Despite strong earnings from Lennar, homebuilders fell after the Commerce Department said the pace of home construction slowed in August.
NEW YORK— U.S. stocks inched higher Tuesday in another cautious day of trading as investors kept an eye on central banks in the U.S. and Japan. Drug companies helped health care stocks make some modest gains, while Exxon Mobil fell on reports it's being investigated by securities regulators. Bond yields slipped and the dollar was little changed as investors...
Botox-maker Allergan is bulking up its drug pipeline with two acquisitions announced Tuesday, both of which target liver disease. Allergan PLC said it's acquiring Tobira Therapeutics Inc. and two potential liver disease treatments in a deal that could be worth almost $1.7 billion. Shares of Dublin- based Allergan slipped nearly 3 percent, or $6.62, to $238.67.
Bill Ackman tells CNBC the past 12 months were the "worst period of performance" of his career, and the implosion of Valeant Pharmaceuticals was mostly to blame.
Pfizer will disclose that painkillers can carry serious risk of addiction and promised not to promote opiates for unapproved uses.
Hillary Clinton accused Pfizer of using legal loopholes to avoid its "fair share" of taxes.
Pfizer secured formal board approval on Sunday for its acquisition of Botox maker Allergan, according to people familiar with the matter.
Pfizer has held early talks with Allergan to discuss what could be the biggest takeover deal this year, according to media reports.
The billionaire tells CNBC he's more bullish on stocks based on valuations than fellow hedge fund titan David Tepper. Ackman also talks Mondelez and his Herbalife short.
Is Valeant Pharmaceuticals CEO Mike Pearson the Billy Beane of pharma deals?
Former Allergan CEO David Pyott tells a Senate hearing the SEC should investigate the Pershing Square-Valeant alliance.
The last 12 months collectively was a period of huge gains in some stocks and stinging losses in others.
Animal health behemoth Zoetis was halted for volatility on Thursday.
The billionaire investor told clients his firm was subpoenaed by prosecutors in New Jersey, according to a letter obtained by CNBC.
Books on Actavis' jumbo nine-tranche bond partly backing the acquisition of Allergan were heard topping $65 billion and are due to close at 1:30 p.m. ET.
Some of the names on the move ahead of the open.
Hedge funds aren't changing their stock holdings much despite poor performance compared with the broader stock market.
Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.